Seth Augenstein | Authors


MD Anderson Partners with Takeda to Develop CAR Natural Killer-Cell Therapy

November 07, 2019

The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited have entered an exclusive license agreement and research agreement to develop and market chimeric antigen receptor-directed natural killer-cell therapies.